<<  Back

Arrowhead Research to Present at Two Nanomedicine-Focused Events in London

Jun 21, 2011 at 12:00 AM EDT
Arrowhead Research to Present at Two Nanomedicine-Focused Events in London PASADENA, Calif. – June 21, 2011 – Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that its President and Chief
Arrowhead Research to Present at Two Nanomedicine-Focused Events in LondonPASADENA, Calif. – June 21, 2011 – Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that its President and Chief Executive Officer Christopher Anzalone, Ph.D., will present at two upcoming nanomedicine-focused events at the Copthorne Tara Hotel in London:
  • SMi 6th Annual RNAi, miRNA and siRNA Conference – “Overcoming a key challenge of RNAi Therapeutics: Effective Systemic Delivery of siRNA in Humans” on June 27 at 12:35 p.m. (London time)
  • SMi Pharmaceutical Nanotechnology: Applications & Commercialization Conference – “Building a Diversified Nanomedicine Company” on June 30 at 11:25 a.m. (London time)

John Rossi, Ph.D., Dean of the Graduate School of Biological Sciences at the Beckman Research Institute City of Hope, Associate Director of Laboratory Research at the City of Hope Comprehensive Cancer Center, and co-founder and member of the Scientific Advisory Board of Arrowhead’s majority owned subsidiary, Calando Pharmaceuticals, Inc., also will present at the SMi 6th Annual RNAi, miRNA and siRNA Conference:

  • “Small RNAs as Triggers for Epigenetic Control of Gene Expression” on June 28 at 9:10 a.m. (London time)
  • Panel Discussion: “Epigenetics in RNAi” on June 28 at 9:30 a.m. (London time)

The RNAi conference will display some of the most promising results achieved in the field of RNAi, from structural determination to specific therapeutic applications, clinical trial considerations and negotiating the regulatory minefield. The pharmaceutical nanotechnology conference, a case study driven event, will address not only the latest scientific developments, but also the know-how required to successfully translate these discoveries and technologies into a commercially successful product.

About Arrowhead Research Corporation

Arrowhead Research Corporation is a clinical stage targeted therapeutics company with development programs in oncology, obesity, and infectious disease. The company leverages its platform technologies to design and develop peptide-drug conjugates (PDCs) which specifically home to cell types of interest while sparing off-target tissues, creates targeted drugs based on the gene silencing RNA interference (RNAi) mechanism, and works with partners to create improved versions of traditional small molecule drugs.

For more information please visit http://www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list to receive news directly, please send an email to ir@arrowres.com 

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Arrowhead Research Corporation's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

Contacts: 
Brandi Floberg

The Piacente Group, Inc.

212-481-2050